Live Breaking News & Updates on Utro biopharma

Stay informed with the latest breaking news from Utro biopharma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Utro biopharma and stay connected to the pulse of your community

Sutro Biopharma Announces Pricing of $75 Million

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...

North-carolina , United-states , Charlotte , Emily-white , Sutro-biopharma , Prospectus-department , Sutro-biopharma-inc , Exchange-commission , Bofa-securities , Tryon-street , South-san , Private-securities-litigation-reform-act

Sutro Biopharma to Host Investor Webcast Highlighting

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...

Sutro-biopharma , Luveltamab-tazevibulin , Emily-white , Drug-administration , Sutro-biopharma-inc , Exchange-commission , Fast-track , Ovarian-cancer , Rare-pediatric-disease , South-san , Private-securities-litigation-reform-act , Nasdaq-stro

Sutro Biopharma (NASDAQ:STRO) shareholders are up 11% this past week, but still in the red over the last three years

It's nice to see the Sutro Biopharma, Inc. ( NASDAQ:STRO ) share price up 11% in a week. But the last three years have...

Sutro-biopharma , Revenue-growth , Utro-biopharma , Nc- , Hare-price , Rofit-growth ,

Sutro Biopharma Announces Oral Presentation at ASCO 2023

- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab...

United-states , Hebron , Israel-general- , Israel , Chicago , Illinois , Canada , Barcelona , Comunidad-autonoma-de-cataluna , Spain , American , Astellas-pharma

Sutro Biopharma Reports Third Quarter 2022 Financial

- STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML are accepted for oral presentation at...

United-states , American , Sutro-biopharma-inc , American-society-of-hematology-annual-meeting , Bill-newell , Chief-executive , American-society , Hematology-annual-meeting , Anti-leukemic-activity , Novel-folate , Acute-myeloid-leukemias

Astellas pays Sutro Bio $90M to partner on cancer drugs that make cold tumors hot

Astellas Pharma has a new partner in the R&D of a type of cancer drug called an antibody drug conjugate (ADC). The Japanese pharma company reached across the Pacific Ocean to collaborate with Sutro Biopharma in a bet that Bay Area-based firm’s technology can deliver more powerful ADCs.

Japan , United-states , Japanese , American , Sutro-biopharma , Astellas-pharma , William-newell , Astrazeneca , Gilead-sciences , American-society-of-clinical-oncology , Serono , Bristol-myers-squibb

Astellas and Sutro Biopharma Announce Worldwide Strategic

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do...

Germany , Tokyo , Japan , United-states , Canada , Astellas-pharma , Kenji-yasukawa , Anniej-chang , Naoki-okamura , Bristol-myers-squibb , Williamj-newell , Merck-sharpe-dohme